Company / Operating Margin
CRISPR Therapeutics AG Operating Margin History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Margin
-18933.7%
FY2025
5-year range
-56190.4% / 40.8%
FY2021-FY2025
Trend
-1414.2%
vs FY2024
Sector context
#135 of 136
Health Care
What the data says
Operating Margin changed -1414% YoY in FY2025, a notable deviation from the 9-year average annual change of -15602%.
Based on SEC 10-K filings.
-18933.7% in FY2025 with a 5-year CAGR of +30361.9%.
Declined from -60.0% to -18933.7% over the past 2 years.
Health Care sector context is included.
Operating Margin over time
Growth rates
- 3-Year Change
- +37256.8pp
- 5-Year Change
- +30361.9pp
- 10-Year Change
- -
Sector benchmark
Bottom 1% in Health CareTop 99% of 136This company -18933.7% Sector average -778.9%
▼
-2330.7% below sector average
Key checks
Key Insights
- In FY2025, operating margin decreased 1414.2% year-over-year.
- Currently 18154.7pp below the Health Care sector average.
- Peak operating margin was recorded in FY2019.
- Lowest operating margin in the period was in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -18933.7% | -1414.2% |
| FY2024 | -1250.4% | -1985.7% |
| FY2023 | -60.0% | +99.9% |
| FY2022 | -56190.4% | -137754.1% |
| FY2021 | 40.8% | +100.1% |
| FY2020 | -49295.5% | -445.9% |
| FY2019 | 14250.0% | +1180.1% |
| FY2018 | -1319.3% | +87.3% |
| FY2017 | -10416.6% | -288.2% |
| FY2016 | -2683.0% | - |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026